Literature DB >> 11879677

Current status and future directions in the pharmacotherapy of epilepsy.

Wolfgang Löscher1.   

Abstract

Considerable progress in the pharmacotherapy of epilepsy has been witnessed during the 20th century. However, despite the development of various antiepileptic drugs, about a third of patients are resistant to current pharmacotherapies. Even in patients in whom pharmacotherapy is efficacious, current antiepileptic drugs do not affect the progression or underlying natural history of the condition. Furthermore, currently there are no drugs available that prevent the development of epilepsy following, for example, head trauma. The rapid expansion of information about the cellular, molecular and genetic mechanisms of epilepsy is expected to lead to more effective therapies, prevention or even a cure for different types of epilepsy. In this article, I assess the current status of antiepileptic therapies and highlight innovative approaches for future treatments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11879677     DOI: 10.1016/S0165-6147(00)01974-X

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  36 in total

Review 1.  Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.

Authors:  Wolfgang Löscher; Claudia Brandt
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Involvement of ionotropic glutamate receptors in the appearance of arecoline tremor in mice.

Authors:  N Ya Lukomskaya; V V Lavrent'eva; L A Starshinova; E P Zhabko; V E Gmiro; L G Magazanik
Journal:  Neurosci Behav Physiol       Date:  2008-05

Review 3.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  NeuroRx       Date:  2005-01

Review 4.  Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.

Authors:  Melissa Barker-Haliski; H Steve White
Journal:  Neuropharmacology       Date:  2019-08-27       Impact factor: 5.250

Review 5.  Lamotrigine add-on for drug-resistant partial epilepsy.

Authors:  Sridharan Ramaratnam; Mariangela Panebianco; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2016-06-22

Review 6.  [Brain tumors and epilepsy].

Authors:  H Stefan; I Blümcke; M Buchfelder
Journal:  Nervenarzt       Date:  2005-10       Impact factor: 1.214

7.  Functional variant in complement C3 gene promoter and genetic susceptibility to temporal lobe epilepsy and febrile seizures.

Authors:  Sarah Jamali; Annick Salzmann; Nader Perroud; Magali Ponsole-Lenfant; Jennifer Cillario; Patrice Roll; Nathalie Roeckel-Trevisiol; Ariel Crespel; Jorg Balzar; Kurt Schlachter; Ursula Gruber-Sedlmayr; Ekaterina Pataraia; Christoph Baumgartner; Alexander Zimprich; Fritz Zimprich; Alain Malafosse; Pierre Szepetowski
Journal:  PLoS One       Date:  2010-09-16       Impact factor: 3.240

8.  Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice.

Authors:  Nima Naderi; Farzad Aziz Ahari; Bijan Shafaghi; Azadeh Hosseini Najarkolaei; Fereshteh Motamedi
Journal:  J Neural Transm (Vienna)       Date:  2008-06-25       Impact factor: 3.575

Review 9.  Channelopathies in idiopathic epilepsy.

Authors:  Sarah E Heron; Ingrid E Scheffer; Samuel F Berkovic; Leanne M Dibbens; John C Mulley
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

10.  Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain.

Authors:  R Clinckers; I Smolders; Y Michotte; G Ebinger; M Danhof; R A Voskuyl; O Della Pasqua
Journal:  Br J Pharmacol       Date:  2008-10-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.